

**UNITED STATES DISTRICT COURT  
DISTRICT OF MARYLAND**

CLAUDIO DE SIMONE,

Plaintiff/Counterclaim Defendant,

EXEGI PHARMA, LLC,

Plaintiff,

v.

VSL PHARMACEUTICALS, INC.,

Defendant/Counterclaim Plaintiff,

LEADIANT BIOSCIENCES, INC., and  
ALFASIGMA USA, INC.

Defendants,

v.

DANISCO USA, INC.,

Counterclaim Defendant.

Civil Action No. TDC-15-1356


**ORDER**

For the reasons stated in the accompanying Memorandum Opinion, it is hereby ORDERED that:

1. Defendant Alfasigma USA, Inc.'s ("Alfasigma") Motion Pursuant to Rules 50 and 59 of the Federal Rules of Civil Procedure and 15 U.S.C. § 1117(a), ECF No. 859, is DENIED.
2. Defendant Ladiant Biosciences, Inc.'s ("Ladiant") Renewed Rule 50 Motion for Judgment as a Matter of Law on Plaintiff Claudio De Simone's Unjust Enrichment Claim and on Plaintiff ExeGi Pharma LLC's False Advertising Claim, ECF No. 861, is DENIED.

3. Defendant VSL Pharmaceuticals, Inc.'s ("VSL") Renewed Motion for Judgment on Plaintiff De Simone's Unjust Enrichment Claim, ECF No. 863, is DENIED.
4. VSL's Motion for a New Trial on Its Declaratory Relief and Breach of Fiduciary Duty Counterclaims, ECF No. 864, is DENIED.
5. VSL, Leadiant, and Alfasigma's Joint Motion for a New Trial on Plaintiffs' Unjust Enrichment and Lanham Act Claims, ECF No. 865, is DENIED.

Date: June 20, 2019



THEODORE D. CHUANG  
United States District Judge